Karisa C. Schreck

Practical management of BRAF inhibitors in glioma: toxicity and resistance

BRAF inhibitors have advanced treatment for patients with BRAF-altered high and low-grade glioma (HGG and LGG, respectively). Clinically-available therapies are effective but require selection by mutation type and careful, proactive toxicity management to maximize patient quality...